On performing an experimental study on mice, Drescher et al. found that CD62L deficient mice had less pronounced metabolic syndrome, lower fat content both visceral and subcutaneous, and developed a lower grade of NAFLD with lesser ballooning degeneration and lower serum transaminases compared to wild type mice [19]. The gene discussed is SELL; the disease is metabolic dysfunction-associated steatotic liver disease.